Patent classifications
A61L2300/622
Microspheres containing therapeutic agents and related methods of use
Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.
Developable Hyaluronic Acid Microspherical Embolic Agent, Preparation Method and Use Thereof
A developable hyaluronic acid microspherical embolic agent includes a hyaluronic acid and an X-ray opaque contrast material; wherein the hyaluronic acid is a modified hyaluronic acid, wherein a modifying method for preparing the modified hyaluronic acid is cross-linking, grafting, esterification, or recombination, and is preferably cross-linking.
METHOD FOR PREPARING DEGRADABLE DRUG-LOADED MICROSPHERE FOR EMBOLIZATION, AND PRODUCT OBTAINED THEREFROM
A method for preparing a degradable drug-loaded microsphere for embolization and a product obtained therefrom, includes the steps of: dissolving a degradable material in an organic solvent, then adding a drug and mixing well to form a suspension or solution; then pouring the drug-containing suspension or solution into an aqueous solution of polyvinyl alcohol, stirring, and thereafter adding water twice for dilution, to prepare the degradable drug-loaded microsphere. The microsphere prepared by the present invention has the advantages of having a controllable particle size, a high drug loading capacity, and a regular spherical shape, being convenient for sieve sizing and accurate particle-size indication, and being accurately targeted to an embolized blood vessel, and the like, and thus has a good application prospect in interventional embolization therapy.
SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY
The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making antibiotic-containing silk scaffold, methods of stabilizing antibiotics in silk scaffolds, and methods for preventing or treating microbial contamination using the antibiotic-containing compositions. Various methods may be used to embed the antibiotic(s) into the silk fibroin-based compositions. The antibiotic-containing compositions of the invention are particular useful for stabilizing antibiotics, preventing bacterial infections, and for medical implants, tissue engineering, drug delivery systems, or other pharmaceutical or medical applications.
Reusable protective template
A reusable protective template is formed by multiple layers: a first body-contacting layer made of a textile fabric and having bactericidal properties (silver ions, claim 2) and water-repelling properties due to chitosan fibres; an intermediate layer with silicone or a polymeric gel, and a third layer made of a textile fabric with means of attachment to a garment.
EXPANDABLE BALLOON CATHETER
Balloon catheter (22) having a coating comprises a primer layer (24) comprising at least one or more substantially hydrophilic compounds, a first layer (26) comprising an inclusion compound; and a second layer (28) comprising a mixture of a hydrophobic polymer, an active therapeutic agent and the inclusion compound.
Cell-free tissued engineered vascular grafts
A composition containing a macrophage inhibitor may be administered in an effective amount to prevent, inhibit or reduce restenosis, thrombus or aneurysm formation in implanted polymeric vascular grafts. The composition may be administered prior to vascular graft implantation, at the same time as vascular graft implantation, following vascular graft implantation, or any combination thereof. Examplary macrophage inhibitors include bisphosphonates, anti-folate drugs and antibodies, preferably in a controlled release or liposomal formulation.
COATED IMPLANTS FOR LONG-TERM CONTROLLED RELEASE OF ANTIBODY THERAPEUTICS
Implants for anti-VEGF therapy provide both stability and controlled release of bevacizumab and other structurally sensitive polypeptides while maintaining protein/peptide stability in the micronized powder; achieving near zero order and complete release (>80%). Cylindrical implants suitable for intravitreal injection.
Titanium nail capable of loading drug and drug-loaded titanium nail and preparing method of the same
The present invention discloses a preparation method of a titanium nail capable of loading a drug. The titanium nail capable of loading a drug includes a titanium nail body capable of loading a drug, and a microporous ceramic layer capable of loading a drug arranged on the surface of the titanium nail body. The steps of the method include: pretreating the surface of the titanium nail body, preparing a microporous mould for hyaluronic acid-alginic acid microspheres, preparing a titanium sol solution, coating film, pore-forming and calcining. It fails to generate the exfoliations and the wear debris to prevent the human body from wear debris disease and reaction to a foreign body. Moreover, various drugs such as the antibacterial drugs, and the drugs for promoting the healing etc. can be loaded, targeted and slow-released, which is good for medical usage.
Hydrogel encapsulated cells and anti-inflammatory drugs
A composition containing biocompatible hydrogel encapsulating mammalian cells and anti-inflammatory drugs is disclosed. The encapsulated cells have reduced fibrotic overgrowth after implantation in a subject. The compositions contain a biocompatible hydrogel having encapsulated therein mammalian cells and anti-inflammatory drugs or polymeric particles loaded with anti-inflammatory drugs. The anti-inflammatory drugs are released from the composition after transplantation in an amount effective to inhibit fibrosis of the composition for at least ten days. Methods for identifying and selecting suitable anti-inflammatory drug-loaded particles to prevent fibrosis of encapsulated cells are also described. Methods of treating a disease in a subject are also disclosed that involve administering a therapeutically effective amount of the disclosed encapsulated cells to the subject.